ABAnders Barasa

Anders Barasa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anders Barasa has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Trends in Guideline-Directed Medical Therapies and Clinical Management in Patients With Prevalent Versus Incident Heart Failure: A Danish Nationwide Study From 1996 to 2022

    by Emma Kidholm Boysen, Lars Køber, Mads Kristian Ersbøll, Trine Kiilerich Lauridsen, Jesper Jensen, Emil Wolsk, Jens Jakob Thune, Mette Rauhe Mouridsen, Christian Ditlev Tuxen, Peter Godsk Jørgensen, et al.

  • Open Access

    Diastolic Dysfunction in Adults with Preserved Ejection Fraction: Prevalence and Predictors in Kenyan Tertiary Referral Hospital

    by Etienne Amendezo, Anders Barasa, Jasmit Shah, Mohamed Jeilan, Mzee Ngunga

    Background Diastolic dysfunction (DD), a precursor to heart failure with preserved ejection fraction (HFpEF), is associated with significant morbidity and mortality. Data on DD in Sub-Saharan Africa (SSA) remain limited. This study aimed to determine the prevalence and describe the clinical and echocardiographic characteristics of DD in a cohort of adult patients at a tertiary referral facility in Kenya. Methods In this prospective cohort study, we reviewed 1,205 echocardiographic examinations performed in a six-month period in 2020 at the Aga Khan University Hospital, Nairobi, Kenya. Diastolic function was assessed based on the 2016 ASE/EACVI guidelines. Patients with preserved left ventricular (LV) systolic function (Left Ventricular Ejection Fraction [LVEF] ≥ 50%) and evidence of diastolic abnormalities were evaluated, and those meeting guideline criteria for DD were included in the final analysis. Results Among the 1,205 echocardiograms reviewed, 43.1% (n = 519) showed at least one diastolic abnormality, and 32.1% (n = 387) met the inclusion criteria. Of these, 53.2% (n = 206) were classified as having severe DD, while 46.8% (n = 181) had borderline DD. The mean age of participants was 62.8 ± 12.3 years. The most common symptoms were dyspnea (54.8%), chest pain (31.5%), and fatigue (27.1%). Hypertension was affecting 78.6%. Multivariate analysis identified the following independent predictors of severe DD: chronic kidney disease (OR: 8.07, 95% CI: 3.25–19.99), preexisting heart failure (OR: 6.04, 95% CI: 3.26–11.17), atrial fibrillation (OR: 5.43, 95% CI: 1.57–18.83), pacemaker implant (OR: 4.95, 95% CI: 1.09–22.5), dyspnea (OR: 3.39, 95% CI: 1.76–6.55), anemia (Hb < 10 g/dL) (OR: 2.04, 95% CI: 1.24–3.36), hypertension (OR: 2.04, 95% CI: 1.22–3.43), advanced age (OR: 1.02, 95% CI: 1.01–1.04), and elevated NT-proBNP (OR: 18.52, 95% CI: 3.36–101.9). Echocardiographic parameters associated with severe DD included LV hypertrophy (OR: 2.67, 95% CI: 1.61–4.4), abnormal global longitudinal strain (OR: 1.66, 95% CI: 1.009–2.74), and low-normal LV systolic function (OR: 1.64, 95% CI: 1.06–2.53). Conclusion This study shows that a third of patients referred for echocardiography at a tertiary referral hospital in Kenya have diastolic dysfunction, the majority severe. Traditional cardiovascular risk factors: hypertension and chronic kidney disease, were strongly associated with severe DD. These findings underscore the importance of early detection and aggressive management of cardiovascular risk factors to prevent the onset and progression of HF in Sub-Saharan Africa.

  • Open Access

    A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure

    by Signe Glargaard, Jakob Hartvig Thomsen, Christian Tuxen, Matias Greve Lindholm, Christian Axel Bang, Morten Schou, Kasper Iversen, Rasmus Vedby Rasmussen, Brian Bridal Løgstrup, Søren Vraa, et al.

    BACKGROUND: TAP-IT (Thoracentesis to Alleviate Cardiac Pleural Effusion–Interventional Trial) investigated the effect of therapeutic thoracentesis in addition to standard medical therapy in patients with acute heart failure and sizeable pleural effusion. METHODS: This multicenter, unblinded, randomized controlled trial, conducted between August 31, 2021, and March 22, 2024, included patients with acute heart failure, left ventricular ejection fraction ≤45%, and non-negligible pleural effusion. Patients with very large effusions (more than two-thirds of the hemithorax) were excluded. Participants were randomly assigned 1:1 to upfront ultrasound-guided pleural pigtail catheter thoracentesis in addition to standard medical therapy or standard medical therapy alone. The primary outcome was days alive out of the hospital over the following 90 days; key secondary outcomes included length of admission and 90-day all-cause mortality. All outcomes were analyzed according to the intention-to-treat principle. RESULTS: A total of 135 patients (median age, 81 years [25th; 75th percentile, 75; 83]; 33% female; median left ventricular ejection fraction, 25% [25th; 75th percentile, 20%; 35%]) were randomized to either thoracentesis (n=68) or standard medical therapy (n=67). The thoracentesis group had a median of 84 days (77; 86) alive out of the hospital over the following 90 days compared with 82 days (73; 86) in the control group ( P =0.42). The mortality rate was 13% in both groups, with no difference in survival probability ( P =0.90). There were no differences in the duration of the index admission (control group median, 5 days [3; 8]; thoracentesis group median, 5 days [3; 7], P =0.69). Major complications occurred in 1% of thoracenteses performed during the study period. CONCLUSIONS: For patients with acute heart failure and pleural effusion, a strategy of upfront routine thoracentesis in addition to standard medical therapy did not increase days alive out of the hospital for 90 days, all-cause mortality, or duration of index admission. The current findings lay the groundwork for future research to confirm the results. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05017753.


  • Symptomatic recovery and pharmacological management in a clinical cohort with peripartum cardiomyopathy

    by Anders Barasa, Valentina Goloskokova, Lars Ladfors, Harshida Patel, Maria Schaufelberger

    Aim: We aimed to characterize the clinical course with focus on pharmacological management of peripartum cardiomyopathy (PPCM) in Sweden. Methods: Twenty-four consecutive patients were retrospectively identified among women presenting with PPCM in Western Sweden. Of these, 14 had concomitant preeclampsia. There was only one fatality. The mean (standard deviation) left ventricular ejection fraction (LVEF) at diagnosis was 35.0 ± 9.9%. Ten women, 47.6%, required intensive care unit (ICU) admission. All patients received β-blockers (BB) and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACE-I/ARB), which were tapered off over a mean/median period of 3.3/2.5 years with only one case of worsening heart failure. The mean follow-up for medication was 7.9 ± 2.6 years. Early and late/non-recovery was defined as New York Heart Association (NYHA) functional class I and NYHA II–IV at one year, respectively. Late recovery was associated with larger LVEDD at diagnosis (56.8 versus 62.4 mm) was associated with late recovery, p = .02. Results and conclusions: PPCM had an overall good prognosis in this cohort. Left ventricular dilation at presentation was a predictor of worse prognosis. Concurrent preeclampsia was common, but was associated with better prognosis. Medication was safely discontinued in 75% of patients.


  • Open Access

    Heart Failure in Late Pregnancy and Postpartum: Incidence and Long-Term Mortality in Sweden From 1997 to 2010

    by Anders Barasa, Annika Rosengren, Tatiana Zverkova Sandström, Lars Ladfors, Maria Schaufelberger


  • Open Access

    Symptoms in women with Peripartum Cardiomyopathy: A mixed method study

    by Harshida Patel, Marie Berg, Anders Barasa, Cecily Begley, Maria Schaufelberger


  • Open Access

    Heart failure in young adults: 20-year trends in hospitalization, aetiology, and case fatality in Sweden

    by Anders Barasa, Maria Schaufelberger, Georgios Lappas, Karl Swedberg, Mikael Dellborg, Annika Rosengren

    To describe trends in incidence and case fatality among younger (18–54 years) and older (55–84 years) Swedish patients with heart failure (HF). Through linking the Swedish national hospital discharge and the cause-specific death registries, we identified patients aged 18–84 years that were discharged 1987–2006 with a diagnosis of HF. Age-specific mean incidence rates per 100 000 person-years were calculated in four 5-year periods. Kaplan–Meier survival curves were plotted up to 3 years. From 1987 to 2006, there were 443 995 HF hospitalizations among adults 18–84 years. Of these, 4660 (1.0%) and 13 507 (3.0%) occurred in people aged 18–44 and 45–54 years (31.6% women), respectively. From the first to the last 5-year period, HF incidence increased by 50 and 43%, among people aged 18–34 and 35–44 years, respectively. Among people ≥45 years, incidence peaked in the mid-1990s and then decreased. Heart failure in the presence of cardiomyopathy increased more than two-fold among all age groups. Case fatality decreased for all age groups until 2001, after which no further significant decrease <55 years was observed. Increasing HF hospitalization in young adults in Sweden opposes the general trend seen in older patients, a finding which may reflect true epidemiological changes. Cardiomyopathy accounted for a substantial part of this increase. High case fatality and lack of further case fatality reduction after 2001 are causes for concern.